FDA Approves Oriahnn For Menstrual Bleeding

TUESDAY, June 2, 2020 (HealthDay News) -- The U.S. Food and Drug Administration has approved the drug Oriahnn to treat menstrual bleeding linked to fibroids.

Oriahnn capsules are a combination of estrogen and progestin consisting of elagolix, estradiol and norethindrone acetate, according to the FDA.

The drug made by AbbVie Inc. has proven effective in two studies where it reduced bleeding by 50% or more over six months.

Oriahnn may result in bone loss over time, which may not completely resolve once treatment is stopped.

The most common side effects are hot flushes, headache, fatigue and irreg> drug package includes a black box warning about the risk of strokes and blood clots, especially in women at risk for these conditions, the FDA said.

MedicalNews
Copyright © 2019 HealthDay. All rights reserved.

QUESTION

What are uterine fibroids? See Answer

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW